Loading clinical trials...
Loading clinical trials...
Single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series of three transnasal sphenopalatine ganglia blocks to measure their effect on headache frequency, headache intensity, headache duration, and use of headache medication.
Age
8 - 17 years
Sex
ALL
Healthy Volunteers
No
St. Louis Children's Hospital
St Louis, Missouri, United States
Start Date
January 2, 2021
Primary Completion Date
February 5, 2021
Completion Date
February 5, 2021
Last Updated
February 10, 2021
Headache Journal
OTHER
Sphenopalatine Block
DRUG
Tx360
DEVICE
Lead Sponsor
Washington University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions